Robert Barnett Naso is a notable inventor based in Menlo Park, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of peptide compounds that target the erythropoietin receptor. With a total of 4 patents to his name, Naso's work has the potential to impact therapeutic methods for treating blood-related disorders.

Latest Patents

Naso's latest patents include innovative formulations of erythropoietin receptor peptide compounds. These compounds act as agonists of the erythropoietin receptor (EPO-R) and are designed to address disorders associated with insufficient or defective red blood cell production. The patents also detail pharmaceutical compositions that incorporate these peptide compounds, along with recommended dosages for effective treatment.

Career Highlights

Throughout his career, Robert Barnett Naso has been associated with Affymax, Inc., a company known for its advancements in biotechnology. His work at Affymax has allowed him to focus on developing therapeutic solutions that can significantly improve patient outcomes in hematological conditions.

Collaborations

Naso has collaborated with esteemed colleagues such as Anne-Marie Duliege and Richard Stead. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the field.

Conclusion

Robert Barnett Naso's contributions to biotechnology through his patents and collaborations highlight his role as a key innovator in the industry. His work continues to pave the way for advancements in treatments for blood disorders, showcasing the importance of innovation in healthcare.